How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
Sarepta Therapeutics' stock slips further as company bows to FDA pressure to halt shipments
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
Sarepta Stock Falls. Why It's Caving Into the FDA and What Comes Next.
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.
Sarepta stock extends decline as company declines FDA call to withdraw drug
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and Drug Administration request to stop selling a drug tied to three deaths.
Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Company Participants Douglas S. Ingram - President, CEO & Director Ian Estepan - Corporate Participant Louise Rodino-Klapac - Corporate Participant Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N.
Sarepta shares plunge 30% as future of its gene therapy appears at risk
Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.
Sarepta shares sink on third gene therapy-linked death
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares pulled back after Thursday's gains on the announcement of a third patient death linked to the company's experimental gene therapies. The patient, who was participating in a Phase 1 trial for Sarepta's approved AAVrh74-based gene therapy targeting limb-girdle muscular dystrophy, died from acute liver failure.
Sarepta Stock Plummets 23%. Here's Why.
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after two teenage boys receiving the treatment died earlier this year.
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.
Sarepta shares soar on restructuring, R&D refocus
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped on a sweeping restructuring plan that includes cutting about 500 jobs, or 36% of its workforce, in a move aimed at reducing annual operating expenses by $400 million by 2026. The biotech company said it will sharpen its focus on high-impact drug development programs, particularly its small interfering RNA (siRNA) platform targeting neurodegenerative and pulmonary diseases such as facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy type 1, and Huntington's disease.
